Cormorant Asset Management’s Solid Biosciences SLDB Stock Holding History

Cormorant Asset Management’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-16,667	Closed	-$2.3M	–	77
2019 Q1	$2.3M	Sell	16,667 -26,865	-62%	-$6.73M	0.16%	61
2018 Q4	$17.5M	Sell	43,532 -1,169	-3%	-$550K	1.42%	28
2018 Q3	$31.6M	Sell	44,701 -1,029	-2%	-$646K	2.06%	19
2018 Q2	$24.4M	Sell	45,730 -1	-0%	-$308	1.81%	22
2018 Q1	$5.14M	Buy	+45,731	New	+$15.4M	0.38%	40

Other funds holding SLDB

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Cormorant Asset Management's SLDB Position: Q2 2019 in Review

Cormorant Asset Management sold out of Solid Biosciences (SLDB) in Q2 2019, closing a stake of 16,667 shares — an estimated $2.3M sold.

Cormorant Asset Management first reported a position in SLDB in Q1 2018 and held it in 5 quarters. The position peaked at $31.6M in Q3 2018. 74 funds tracked by Wall St. Rank hold SLDB as of Q2 2019.

Cormorant Asset Management reported no remaining Solid Biosciences position as of Q2 2019 after selling out during the quarter.
Cormorant Asset Management sold 16,667 Solid Biosciences shares in Q2 2019, an estimated $2.3M.
Cormorant Asset Management first reported a position in Solid Biosciences in Q1 2018 and held it in 5 quarters.
Cormorant Asset Management's Solid Biosciences position peaked at $31.6M in Q3 2018.
74 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2019.

Based on Cormorant Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.